Biotest
Biotest AG, a leading player in the biopharmaceutical industry, is headquartered in Dreieich, Germany. Founded in 1946, the company has established itself as a pioneer in the development and production of immunoglobulins and blood plasma products. With a strong focus on therapeutic areas such as immunology and haematology, Biotest is committed to enhancing patient care through innovative solutions. The company’s core offerings include high-quality plasma-derived therapies, which are distinguished by their rigorous quality standards and advanced manufacturing processes. Biotest has achieved significant milestones, including the expansion of its global presence, with operations spanning Europe, North America, and Asia. Renowned for its commitment to research and development, Biotest continues to solidify its market position as a trusted provider of essential biopharmaceuticals, contributing to improved health outcomes worldwide.
DitchCarbon Score
How does Biotest's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest's score of 36 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotest's reported carbon emissions
In 2022, Biotest reported total carbon emissions of approximately 18,185,600 kg CO2e from Scope 1 and 930,500 kg CO2e from Scope 2, resulting in a combined total of about 19,116,100 kg CO2e. This marks a significant increase from 2021, where emissions were approximately 2,054,400 kg CO2e, with Scope 1 emissions contributing about 1,129,500 kg CO2e and Scope 2 emissions at around 711,000 kg CO2e. Biotest's emissions data is cascaded from its parent company, Grifols, S.A., indicating a corporate family relationship that influences its climate commitments. However, there are currently no specific reduction targets or initiatives disclosed by Biotest, nor are there any emissions reported for Scope 3. The company has not established any Science-Based Targets Initiative (SBTi) reduction targets, nor does it appear to have made any formal climate pledges. As a current subsidiary of Biotest Aktiengesellschaft, its sustainability efforts may align with broader corporate strategies, but specific commitments remain unspecified. Overall, Biotest's emissions data reflects a need for enhanced climate action and transparency in its sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 893,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 16,537,200 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biotest is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
